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Abstract
Background: Polypharmacy with psychoactive drugs is an increasingly common and debatable
contemporary practice in clinical psychiatry based more upon experience than evidence. The
objective of this study was to evaluate the prevalence and conditioners of polypharmacy in
psychiatric patients.
Method: A cross-sectional survey was carried out using the Canary Islands Health Service Clinical
Records Database. A representative sample (n = 2,647) of patients with mental disorders receiving
psychotropic medication was studied.
Results: The mean number of psychoactive drugs prescribed was 1.63 ± 0.93 (range 1–7). The rate
of polypharmacy was 41.9%, with 27.8% of patients receiving two drugs, 9.1% receiving three, 3.2%
receiving four, and 1.8% of the patients receiving five or more psychotropic drugs. Multiple
regression analysis shows that variables sex and diagnosis have a predictive value with regard to the
number of psychotropic drug used, being men and schizophrenic patients the most predisposed.
Benzodiazepines were the more prevalent drugs in monotherapy, while anticonvulsants and
antipsychotics were the more used in combination with other treatment. A questionable very high
degree of same-class polypharmacy was evidenced, while multi-class, adjunctive and augmentation
polypharmacy seem to be more appropriate.
Conclusions: Almost half of the psychiatric patients are treated with several psychotropics.
Polypharmacy is common and seems to be problematic, especially when same class of drugs are
prescribed together. Some diagnoses, such as schizophrenia, are associated with an increase risk
of Polypharmacy but there is a lack of evidence based indicators that allows for quality evaluation
on this practice.
Background
The etymology of the word polypharmacy derives from
poly, from the Greek word polus (many, much) and phar-
macy, from the Greek word pharmakon (drug, poison)
and literally means many drugs [1]. According to Werder
and Preskorn [2] the word polypharmacy first appeared in
the medical literature in 1959 in the New England Journal
of Medicine [3] and in the psychiatric literature in 1969 in
an article citing its incidence at a state mental hospital [4].
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The concurrent use of multiple psychoactive medications
in a single patient, i.e. polypharmacy, is increasingly com-
mon and debatable contemporary practice in clinical psy-
chiatry. This concomitant use of psychiatric drugs is based
more probably upon experience than evidence [5] and is
still hampered by a lack of systematic research. The great
diversity of medications now available for the treatment
of patients with psychiatric disorders, along with the
increased safety of many of the new agents and probably
the pressures of pharmaceutical industry, have created
new opportunities for the use of multiple medications for
a single condition. However, the history of medicine
includes many examples where limited knowledge has led
to widespread acceptance of practices that were later
found to be inappropriate [6]. At the present time there is
a compelling need of further studies about psychiatric
drug combination treatments before clinical recommen-
dations can be made.
Concerns with polypharmacy include the possibility of
cumulative toxicity [7] and increased vulnerability to
adverse events [8], as well as adherence issues which
emerge with increasing regimen complexity [9]. Another
serious concern with polypharmacy is the lack of evi-
dence-based strategies available today to guide this prac-
tice [6] and the problem of drug costs for polypharmacy
patients and how much of our always limited public
resources it is possible to allocate to this treatment strategy
[10].
The objective of the present study was to analyse the prev-
alence of polypharmacy with psychiatric drugs among
patients attended by both general practitioners and psy-
chiatrists working for the Canary Islands Health Service
and affected by mental disorders, identifying the possible
predictors of polypharmacy in psychiatric clinical
practice.
Methods
The present study is based on a representative sample of
the citizens living at Gran Canaria island (755.489 inhab-
itants, density of population, 484 inhabitants/km2, 42
basic zones of health and 429 General Practitioners)
attended by the Canary Islands Health Service (CIHS)
with a diagnosis of mental disorder and under psychop-
harmacological treatment.
Patients were randomly selected from Primary Health
Care Centres that were using a comprehensive electronic
database system for keeping medical records and writing
prescriptions (OMI-AP Database Program) [11]. As the
system is not yet completely implemented in the whole
territory, a bias toward the population living in the main
urban areas (80% of the population) is assumed. Most
patients were diagnosed and prescribed by their general
practitioners, but approximately 1 in 5 were referred to the
community mental health care units were psychiatrists
diagnosed, and prescribed for the first time. In almost all
cases the follow up of patients, and the repeated prescrip-
tions, were made by the general practitioners of the pri-
mary care health centres.
The sample comprised 2,647 patients, with 66.3% female
and 33.7% male. The mean age was 50.1 ± 16.8 years
(range 15–90). Women registered a higher mean age than
men (51.7 ± 16.8 vs. 48 ± 16.2). Other socio-demographic
and clinical characteristics of the sample studied are
shown in Table 1.
Prescription data were retrieved from a cross-sectional sur-
vey carried out using the CIHS OMI-AP Database [11].
OMI-AP Database includes an electronic case record of
every patient attended at the Primary Care Centres that
contains all the prescriptions for each patient, providing
information about the drug prescribed, its dosage and
duration, the diagnosis of the patient, and producing the
print-out of the corresponding prescriptions. All active
episodes of psychiatric conditions been diagnosed and
treated at December 20th 2003 were selected for analysis.
No follow-up of these patients were intended nor was it
possible at the present time of the development of the
program. Despite that the database also contains dosages,
the system is not reliable for this data.
In this paper, polypharmacy will refer broadly to the con-
currently use of two or more psychiatric medications in
the same patient. Possible predictors of polypharmacy
were analyzed by stepwise linear multiple regression.
The diagnoses were registered by the attending physician
according to ICD-10 [12], using the OMI-AP database cor-
responding tool, and grouped into the main ICD-10 chap-
ter V (mental and behavioural disorders) diagnostic
categories, which include: organic including symptomatic
mental disorders (F0); mental and behavioural disorders
due to psychoactive substance abuse (F1); schizophrenia,
schizotypal and delusional disorders (F2); mood (affec-
tive) disorders (F3); neurotic, stress-related and somato-
form disorders (F4); behavioural syndromes associated
with physiological disturbances and physical factors (F5);
disorders of the adult personality and behaviour (F6); and
mental retardation (F7). Insomnia was considered as a
separate diagnostic category since a high number of
patients received psychotropic drugs to treat this symp-
tom exclusively.
For evaluation purposes the drugs were divided into the
common groups of psychotropics: antipsychotics, antide-
pressants and tranquillisers (including hypnotics,
whereby benzodiazepines were predominantly used). TheBMC Psychiatry 2004, 4:18 http://www.biomedcentral.com/1471-244X/4/18
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following drugs were also recorded separately: lithium
preparations, the group of anticonvulsants that are
increasingly being used for psychiatric indications and
anti-parkinsonian drugs.
In order to describe the impact and appropriateness of
polypharmacy in greater detail, we have divided polyp-
harmacy in the five categories suggested by the National
Association of State Mental Health Program Directors
(NASMHPD) [6] that includes:
Same-Class Polypharmacy
The use of more than one medication from the same med-
ication class (e.g. two selective serotonin reuptake inhibi-
tors, such as fluoxetine plus paroxetine).
Multi-Class Polypharmacy
The use of full therapeutic doses of more than one medi-
cation from different medication classes for the same
symptom cluster (e.g. the use of lithium along with an
atypical antipsychotic, such as fluoxetine plus olanzapine
for treatment of mania).
Adjunctive Polypharmacy
The use of one medication to treat the side effects or sec-
ondary symptoms of another medication from a different
medication class (e.g. the use of trazadone along with
buproprion for insomnia).
Augmentation
The use of one medication at a lower than normal dose
along with another medication from a different medica-
tion class at its full therapeutic dose, for the same symp-
tom cluster (e.g. the addition of a low dose of haloperidol
in a patient with a partial response to risperidone) or the
addition of a medication that would not be used alone for
the same symptom cluster (e.g. the addition of lithium in
a person with major depression who is currently taking an
antidepressant).
Total Polypharmacy
The total count of medications used in a patient, or total
drug load.
Results
Table 1 shows the sample distribution according to sex,
age, diagnosis and psychotropic drugs prescribed. The
mean number of psychotropic drug used by the patients



















P Value Sd R β
Age N.S. -0.005
<18 years 7 1.4 ± 0.8 71.4 14.3 14.3 x x x x 0.785
18–25 years 93 1.5 ± 0.9 67.7 21.5 4.3 4.3 2.2 x x
25–45 years 966 1.7 ± 0.9 55.3 30.3 8.9 4.0 0.8 0.5 0.1
45–65 years 926 1.7 ± 1.0 56.7 26.3 11.2 3.5 1.6 0.4 0.2
>65 years 655 1.5 ± 0.8 62.9 27.2 7.0 1.7 0.9 0.2 0.2
Gender 0.012 -0.048
Male 892 1.7 ± 1.0 55.8 27.2 9.8 4.8 1.5 0.7 0.2
Female 1,755 1.6 ± 0.9 59.3 28.1 8.8 2.5 1.0 0.2 0.1
Diagnosis <0.0005 -0.233
F0 68 1.7 ± 1.0 55.9 25.0 11.8 5.9 1.5 x x
F1 167 1.8 ± 0.9 43.7 33.5 17.4 4.8 0.6 x x
F2 113 2.9 ± 1.6 22.1 25.7 14.2 20.4 10.6 5.3 1.8
F3 659 1.9 ± 1.0 43.2 34.7 15.0 4.2 2.0 0.5 0.3
F4 1,344 1.4 ± 0.7 65.4 26.5 6.4 1.6 x 0.1 x
F 5 6 1 . 5  ±  0 . 5 5 0 5 0 xxxxx
F6 10 2.8 ± 1.8 40 10 10 10 30 x x
F7 10 2.0 ± 1.3 40 40 10 x 10 x x
Insomnia 268 1.2 ± 0.4 85.1 14.9 x x x x x
Total 2,647 1.6 ± 0.9 58.1 27.8 9.1 3.2 1.2 0.4 0.2
Sd R β :Standardized regression coefficient βBMC Psychiatry 2004, 4:18 http://www.biomedcentral.com/1471-244X/4/18
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was 1.63 (S.D. 0.93, range 1–7). Half of the patients
(58.1%) were under monotherapy treatments, while
27.8% received two drugs, 9.1% received three, and 5%
received four or more drugs.
Polypharmacy with psychoactive drugs was more preva-
lent in men than in women, in those with aged between
25 and 45 years, and in patients with diagnosis included
in the schizophrenia, schizotypal and delusional disor-
ders ICD-10 category.
The multiple regression analysis includes the variables
age, gender and diagnosis but only the variables sex and
diagnosis have a predictive value with regard to the
number of psychotropic drugs used. In particular, diag-
noses was the most reliable predictor (table 1).
Considering the drugs used (table 2), tranquillisers were
the most frequent medication, since they were used by
87.3% of the patients (84.4% benzodiazepines), followed
by the Selective Serotonin Reuptake Inhibitors (SSRI)
used by 29% of patients, conventional antipsychotics
with 5.2% and anticonvulsants with 4.8%.
The medication more prevalent in monotherapy was the
group of benzodiazepines since more than half of these
drugs were used alone. On the other hand, anticonvul-
sants and antipsychotics were the drugs most used in com-
bination with other psychoactive medications.
Multi-Class Polypharmacy was the most prevalent type of
polypharmacy evidenced in the sample affecting 20.9% of
patients. The association of an SSRI with a benzodi-
azepine was present in 13.7% of patients, while 1.2% of
patients were treated with the association of a tricyclic
antidepressant and a benzodiazepine.
Same-Class polypharmacy was demonstrated in 18.5% of
patients mainly as a result of patients treated with several
benzodiazepines (16.2%), up to five at the same time to
the same patient. The association of two conventional
antipsychotics or two anticonvulsants were evidenced in
0.6% of patients.
Adjunctive polypharmacy was present in 1.5% of patients
and consists mainly in the association of a conventional
antipsychotic with an anti-parkinsonian drug. Augmenta-
tion polypharmacy was present in only 1% of patients
consisting basically in the association of lithium and
antidepressants.
Table 3 shows the percentages of patients prescribed with
the different psychotropic medications according to diag-
noses either in monotherapy or polypharmacy. In
patients with organic including symptomatic mental dis-
orders (F0, table 3), benzodiazepines (BZDs) and atypical
antipsychotics were the drugs most used both alone as
well as in combination. SSRIs were used predominantly as
monotherapy. The more prevalent prescriptions include:
14.7% of patients with one SSRI, 14.7% with one benzo-
diazepine, 13.2% with one atypical antipsychotic, 7.4%
with one conventional antipsychotic, 7.4% with the asso-
ciation of an atypical antipsychotic and one benzodi-
azepine, and 4.4% with the combination of an atypical
antipsychotic and two BZDs
Table 2: Medications prescribed in the total sample of 2647 valid cases.
% of patients using this drug % Monotherapy
Tranquillisers 87.3 51.1
Benzodiazepines 84.4 54.0
No Benzodiazepines 2.9 34.5
Antidepressants 37.5 23.2
SSRIs 29.0 24.1
Tricyclic Antidepressants 4.2 23.8






Anti-parkinsonian drugs 1.7 0
Lithium 0.5 20.0
1 Conventional antipsychotic mainly include, among others: Haloperidol and Chlorpromazine. 2. Atypical antipsychotic mainly include, among 
others: Olanzapine and Risperidone. SSRIs: Selective Serotonin Reuptake InhibitorsBMC Psychiatry 2004, 4:18 http://www.biomedcentral.com/1471-244X/4/18
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In patients with mental and behavioural disorders due to
psychoactive substance abuse (F1, table 3), is interesting
to note that almost the totality of them received tranquil-
lisers, mainly BZDs. A very high proportion of the BZDs
used were in combination or with another benzodi-
azepine or with other psychoactive drugs. It is remarkable
the small proportion of patients treated with antipsychot-
ics in this diagnostic category. The more prevalent pre-
scriptions include: 32.9% of patients with one
benzodiazepine, 12.6% with two benzodiazepines, 7.8%
of patients received 2 BZDs and one no benzodiazepine-
tranquilliser, 7.2% received one SSRI and one BZD while
4.2% received one SSRI plus two BZDs.
Patients affected by schizophrenia, schizotypal and delu-
sional disorders (F2, table 3), were predominantly treated
through polypharmacy, being atypical antipsychotics the
most prevalent option used. The figures reached by depot
neuroleptics show that these drugs have relevant role to
play. The use of anti-parkinsonian drugs reflect the pat-
tern of neuroleptics used. It is remarkable the high pro-
portion of patients using anticonvulsants and that more
than a half of the patients received benzodiazepines. The
more prevalent prescriptions include; 9.8% of patients
with one atypical antipsychotic, 7.1% of patients with one
BZD, 5.3% receiving one atypical antipsychotic plus one
BZD and 3.5% receiving one conventional antipsychotic.
In the patients with mood or affective disorders (F3, table
3), BZDs were the more prevalent drugs used, since two-
thirds of patients received them, mainly in combination.
SSRIs were the most frequent prescribed antidepressants,
mostly in combination with BZDs. However, tricyclic
antidepressants are still prescribed to 8.6% of patients.
Anticonvulsant were used only by 6.6% of the patients
and lithium only was used by 1.4% of patients. The more
prevalent prescriptions include: 22.8% of patients receiv-
ing one SSRI plus one BZD, 22.2% receiving only one
BZD, 16% receiving one SSRI alone, and 7.4% of patients
receiving one SSRI plus two BZDs.
Patients with neurotic, stress-related and somatoform dis-
orders (F4, table 3) were treated mainly through mono-
therapy with benzodiazepines. The combination of a SSRI
with a BZD was the most prevalent polypharmacy strat-
egy. Antipsychotics were used by 4% of patients and anti-
convulsants by 3.5% of them. The more prevalent
prescriptions include: 57.8% of patients receiving one
benzodiazepine, 14.7% receiving one SSRI plus one BZD,
7.5% receiving two BZDs and 4.6% of patients receiving
one SSRI alone.
Discussion
The study of the polypharmacy phenomenon in psychia-
try is inherently complex. Most diagnostic categories in
psychiatry have not been shown to be valid because they
are not discrete entities with natural boundaries that sep-
arate them from other disorders [13]. Moreover, diagnos-
tic systems such as DSM-IV [14] and ICD-10 [12] foster
diagnosing of comorbid conditions. A person with three
different diagnoses might need three different treatments
[15].
Table 3: Percentages of patients prescribed different psychotropic medications, either in monotherapy or polypharmacy, according to 
diagnoses.
F0 F1 F2 F3 F4
Tranquillisers
Benzodiazepines 45.6 85.6 54.8 74.6 91.1
No Benzodiazepines 11.8 24.6 1.8 0.9 0.4
Antidepressants
SSRIs 23.5 19.8 10.6 53.9 25.5
Tricyclic Antidepressants 2.9 5.4 7.1 8.6 2.8
Other Antidepressants 5.9 - 6.2 9.4 2.1
Antipsychotic
Conventional1 26.4 5.4 38.9 3.5 2.6
Atypical2 30.9 6.0 43.4 2.4 1.4
Depot - - 22.1 0.5 -
Anticonvulsants 1.5 6.6 20.3 6.6 3.5
Anti-parkinsonian drugs 5.9 - 32.7 0.3 0.1
Lithium --- 1 . 4 0 . 1
Average no. of psychotropics 1.7 ± 0.9 1.9 ± 0.9 2.9 ± 1.6 1.9 ± 1.0 1.4 ± 0.7
1 Conventional antipsychotic mainly include, among others: Haloperidol and Chlorpromazine. 2. Atypical antipsychotic mainly include, among 
others: Olanzapine and Risperidone. SSRIs: Selective Serotonin Reuptake Inhibitors (F0): Organic including symptomatic mental disorders (F1): 
Mental and behavioural disorders due to psychoactive substance abuse (F2): Schizophrenia, schizotypal and delusional disorders (F3): Mood 
(affective) disorders (F4): Neurotic, stress-related and somatoform disordersBMC Psychiatry 2004, 4:18 http://www.biomedcentral.com/1471-244X/4/18
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In addition, there is some confusion referring to the clas-
sification of psychiatric drugs since no standard criteria
exist for the assignment of a single psychiatric drug to a
group of substances and medications are arbitrarily
grouped into medication classes, which do not always
reflect their degree of pharmacological similarity. The
classification of a drug can depend on its pharmaceutical
basic schedule, biochemical mechanism, produced effects
or the administrator's subjective intention. Furthermore,
some single medications are by itself "polypharmacy-in-a-
pill" since their complex mechanism of action involves
effects on multiple receptors [16]. In addition, nowadays,
many single medications have been approved for multiple
indications.
Moreover, there are more drugs available, being aggressive
promoted [17,18] and new groups of drugs used as psy-
chotropics (e.g. anticonvulsants, β-blockers).
To define what constitutes an adequate psychotropic drug
prescription is a complex task since it implies the consid-
eration of pharmacological, clinical, social and economic
aspects. This complexity probably contributes to the great
existing variation in the volume and type of drugs pre-
scribed in different countries, within one country and
even within a single institution between individual doc-
tors [19,20]. Some authors consider that the concept of
adequate prescription is almost as abstract as that of
health [21].
Finally, another question that makes difficult any analysis
is the fact that the psychiatric medication provides the
doctor with an opportunity to "do something" and to pre-
scribe a "rational treatment" for the non-specific psycho-
logical problems and for the various social problems from
patients in a manner which complies with the expecta-
tions associated with the role of a doctor [22].
The closure of psychiatric hospitals, psychiatric beds
steadily decreasing, and a community psychiatry that has
struggled for years to treat the most seriously ill individu-
als within the constraints of severely limited resources
probably promote the polypharmacy of the most severe
patients [23].
The prescription database of OMI-AP program permitted
us to estimate the prevalence of concurrently use of more
than one psychotropic medication in the treatment of psy-
chiatric disorders. Prescription databases have been dem-
onstrated to be a reliable source of information to analyze
polypharmacy in other studies [24,25]. Although the
database contains information about the prescribed daily
dose and duration of treatment, we consider at the present
time that this information is not reliable enough to be
analysed.
Research that examines the concurrent use of multiple
psychotropic medications in outpatient populations is
scanty. The existing data are confined to open-labelled or
case studies that investigate the adding of new drugs to
resistant cases. Nonetheless, more good information
about polypharmacy is available at the inpatient care level
[15,26].
The results obtained in our study about prescription of
psychotropic medications are in accordance to those
obtained in previous pharmacoepidemiological studies in
the same area about psychotropic use [19,20,27,28]. We
registered in the same population a high prevalence of
benzodiazepines prescriptions but it seems necessary to
comment that, as it was shown in that study, that most of
the anxiolytic prescriptions were written for dosages well
below the Defined Daily Dose (DDD) (77.1% of cases),
and in only 10% of all anxiolytic prescriptions was the
prescribed dose in agreement with the DDD. This is
important information when making any inference from
drug consumption statistics. It is also remarkable that
apart from being used in low doses, anxiolytics were also
frequently prescribed as a single daily dose 'at supper' or
'before going to bed' (48.6% of prescriptions).
In our study, males were more exposed than women to
polypharmacy with psychotropic medications and gender
was one of the variables that explained the difference in
the logistic regression. Furthermore our results do not
show a clear relationship between age and polypharmacy
with psychotropic drugs, which is a frequent fact in other
studies about general polypharmacy [29,30]. We have no
explanation for these findings apart from the different
diagnostic profiles in the comparative studies, and the
different epidemiological distribution of psychiatric diag-
noses in the population, especially regarding gender.
Prescription databases do not usually include information
about the morbidity for which the drug was prescribed
and only few studies have focused on health problems as
predictors of polypharmacy, with none of them employ-
ing a sample of the general population as study base [31].
Our results shown that psychiatric diagnosis was the most
reliable predictor for polypharmacy, being the patients
affected by schizophrenia, schizotypal and delusional dis-
orders the most predisposed to develop polypharmacy.
The high prevalence of polypharmacy in psychiatry evi-
denced in our study is not substantiated on research liter-
ature that documents its safety and effectiveness.
Polypharmacy with psychiatric medications is a growing
practice that is derived from clinical experience, small tri-
als and case reports [11]. Drug combinations often repre-
sent 'uncontrolled experiments', with unknown potential
for toxic effects.BMC Psychiatry 2004, 4:18 http://www.biomedcentral.com/1471-244X/4/18
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Currently, there is no evidence to justify same-class poly-
pharmacy; our study shows a high degree of this kind of
inappropriate polypharmacy that should be avoided.
However, there is growing evidence of a wide range of sit-
uations where multi-class polypharmacy, adjunctive poly-
pharmacy and augmentation are safe and effective
treatments. In the face of this evidence, however, total
polypharmacy is a growing concern. In our study, multi-
class polypharmacy was a prevalent issue that seems to be
appropriate used. Nevertheless, adjunctive polypharmacy
and augmentation were little evident in the patients
studied.
At the present time, psychiatric clinical practice needs to
develop indicators for an appropriate polypharmacy of
mental disorders. However, it is necessary to consider that
the current standard for evaluation of psychiatric drugs,
based on randomized controlled clinical trials, although
is adequate to compare single medications, it fails when
trying to study every potential drug combination.
Conclusions
Polypharmacy with psychotropic drugs is a prevalent pre-
scription practice in patients with mental disorders in the
Canary Islands. Men are more exposed to be treated with
multiple psychotropic medications and the diagnosis of
the patient is the most reliable predictor for polyphar-
macy with these drugs. Prescription databases can be used
to estimate epidemiological measures of polypharmacy
and to identify which patients are at risk for polyphar-
macy in order to develop proper interventions that mini-
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